Vote Scores

Home / Companies / Arrowhead Pharmaceuticals, Inc.

Company · votes reported on Form N-PXARWR · SEC company no. 879407

Arrowhead Pharmaceuticals, Inc.

How funds and institutional managers reported voting their shares, year to 30 June 2026

Filers reporting
521year to 30 June 2026
Against management on pay
68.5%335 of 489 reporting filers
Same, by reported shares
63.5%shares reported on Form N-PX
Meetings on file
3across 3 seasons
28.0% for65.4% against6.6% other68.5% against management517 filers on say-on-pay

foragainstabstain, withhold or otheramber tick: the portion cast against management

521 Form N-PX filers reported votes at Arrowhead Pharmaceuticals, Inc. for the year to 30 June 2026, across 2 meetings.

On the advisory vote on executive pay, 335 of the 489 filers that reported a position voted against management (68.5%), 61.9 percentage points above the median company on this site (6.6%). By reported shares the figure is 63.5% (median 2.9%). These are shares of the filers reporting on Form N-PX, not of all votes cast at the meeting.

Meetings

Meeting dateSeasonFilers reportingItemsAgainst management on pay
19 Mar 2026year to 30 June 2026519468.5%
12 Mar 2025year to 30 June 2025396426.6%
14 Mar 2024year to 30 June 202442536.4%

Meetings with 20 or more reporting filers have their own page with every item. Dates are as filers typed them; dates up to three days apart are treated as one meeting.

Say-on-pay: this company and the median

year to 30 June 2026Arrowhead Pharmaceuticals, Inc.Median company
Reporting filers voting against management68.5%6.6%
Reported shares voted against management63.5%2.9%

Among filers reporting on Form N-PX. The median is over 3,799 companies with a say-on-pay item reported by 20 or more filers.

How the largest families voted

Meeting of 19 Mar 2026: say-on-pay and each shareholder proposal that could be told apart.

FamilySay-on-pay
VanguardAgainst *
BlackRock and iSharesAgainst *
FidelityAgainst *
DimensionalAgainst *
State Street and SPDRFor
American CenturyFor
Franklin TempletonAgainst *
InvescoAgainst *
EquitableAgainst *
Charles SchwabAgainst *
Nuveen and TIAAFor
ProShares and ProFundsAgainst *
John Hancock and ManulifeAgainst *
Morgan Stanley, Eaton Vance and CalvertFor
J.P. MorganAgainst *
Goldman SachsFor
WisdomTreeAgainst *
PGIM and PrudentialAgainst *
Jackson National fundsAgainst *
Northern Trust and FlexSharesFor
SEIAgainst *
T. Rowe PriceAgainst *
ThriventAgainst *
Lincoln FinancialFor
VoyaAgainst *
First TrustAgainst *
Russell InvestmentsAgainst *
NationwideAgainst *
Victory CapitalAgainst *
Brighthouse FundsAgainst
Guggenheim and RydexAgainst *
Columbia ThreadneedleAgainst *
BNY MellonAgainst *
PrincipalAgainst *
Pacific Life fundsAgainst *
Global XAgainst *
TransamericaAgainst *
Federated HermesFor
AllianceBernsteinAgainst *
DWSAgainst *
AllspringAgainst *
MassMutualAgainst *
VirtusAgainst *
Janus HendersonAgainst *
Neuberger BermanAgainst *
Natixis and Loomis SaylesAgainst *
Lord AbbettAgainst *
BairdFor

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

By season

SeasonFilers reportingAgainst management on pay, filersBy reported sharesSay-on-pay split
year to 30 June 20244266.4%0.2%
year to 30 June 202539926.6%6.5%
year to 30 June 202652168.5%63.5%

Category mix

Share of the vote records reported for this company, by the category filers chose.

CategoryVote recordsShare
DIRECTOR ELECTIONS6,40462.9%
SECTION 14A SAY-ON-PAY VOTES2,55625.1%
AUDIT-RELATED8788.6%
COMPENSATION3453.4%

Questions

How did large funds vote at Arrowhead Pharmaceuticals, Inc.?

For the year to 30 June 2026, 489 Form N-PX filers reported a say-on-pay vote at Arrowhead Pharmaceuticals, Inc.; 335 voted against management (68.5%). The table on this page lists the position of each of the largest fund families on say-on-pay and on each shareholder proposal that could be told apart in the filings.

Were there shareholder proposals at Arrowhead Pharmaceuticals, Inc.?

No proposal from security holders was reported by enough filers to be shown for the year to 30 June 2026.

Is this the meeting result?

No. The figures are shares of the funds and managers that file Form N-PX, and of the shares they reported. Holders that do not file the form (individuals, most foreign investors, insiders) are not included, so the split here can differ widely from the certified result, which Arrowhead Pharmaceuticals, Inc. reports on Form 8-K.

Where does the data come from?

From Form N-PX filings on the SEC's EDGAR system, grouped by company. Filers type company names and meeting dates themselves; this site groups spellings of the same company and folds meeting dates up to three days apart. Data runs through 23 Sep 2026; the median compares 3,799 companies.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Arrowhead Pharmaceuticals, Inc., grouped by company. The name is the most common spelling among filers; the ticker and SEC company number come from the SEC company tickers file, matched on the exact name. Not verified by the SEC. Filings read through 23 Sep 2026; page built 26 Sep 2026.